Statin Applications in Pancreatic Cancer Management

Statins are HMG‐CoA reductase inhibitors commonly prescribed to lower cholesterol. Over the past decade, research has extended their use beyond lipid control to explore anticancer properties, particularly in pancreatic ductal adenocarcinoma (PDAC), a malignancy with dismal prognosis. Preclinical studies indicate that statins interfere with key pathways in cholesterol biosynthesis and membrane dynamics, thereby inducing apoptosis and sensitising tumour cells to standard chemotherapeutics. Mechanistically, statin‐mediated inhibition of the mevalonate pathway diminishes prenylation of small GTPases, disrupts lipid raft composition and attenuates prosurvival signalling such as PI3K/AKT. Epidemiological analyses also suggest that post‐diagnosis statin use may be associated with improved survival in low‐grade resectable tumours and that long‐term use could reduce the risk of PDAC onset. Despite these promising observations, the heterogeneity in statin potency, bioavailability and tumour microenvironment interactions necessitates further clinical validation. Current efforts focus on optimising statin selection, dose and combination strategies to enhance antitumour efficacy and overcome resistance mechanisms in PDAC.

Research from Nature Portfolio

Recent studies have examined the chemopreventive and mechanistic effects of statin use in PDAC risk and tumour biology. One investigation utilised a large case–control design to assess exclusive and combined use of statins and aspirin, revealing that statin monotherapy was associated with a substantial reduction in PDAC occurrence independent of aspirin use. The protective effect appeared dose‐dependent and most pronounced in high‐risk subgroups, including older, obese and non‐diabetic individuals. Another study compared the transcriptional impact of various statins on human PDAC cell lines, demonstrating that individual statins differ markedly in their modulation of the mevalonate pathway, cell cycle regulation, DNA replication, apoptosis and cytoskeletal signalling. Differences in intracellular statin concentrations were found to contribute to variations in anticancer efficacy, suggesting that pharmacokinetic properties must be accounted for when selecting statins for PDAC intervention.

Statin Applications in Pancreatic Cancer Management publication trend

The graph below shows the total number of articles in statin applications in pancreatic cancer management across all publications each year (not limited to Nature Index journals).

Technical terms

Pancreatic ductal adenocarcinoma (PDAC): The most common and aggressive form of pancreatic cancer, originating in the ductal epithelium.

Statins: A class of drugs that inhibit HMG‐CoA reductase, the rate‐limiting enzyme in cholesterol synthesis.

Mevalonate pathway: A metabolic cascade responsible for the production of cholesterol and isoprenoids essential for cell function.

Lipid rafts: Cholesterol‐enriched microdomains within cellular membranes that organise signalling complexes.

Apoptosis: Programmed cell death involving a cascade of molecular events leading to controlled elimination of cells.

Chemoresistance: The ability of cancer cells to withstand the effects of chemotherapeutic agents, often via adaptive signalling or metabolic reprogramming.

References

1. Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria. International Journal of Molecular Sciences (2023).
2. The Association of Statin Use after Cancer Diagnosis with Survival in Pancreatic Cancer Patients: A SEER-Medicare Analysis. PLOS ONE (2015).
3. Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. Scientific Reports (2017).
4. Variability in statin-induced changes in gene expression profiles of pancreatic cancer. Scientific Reports (2017).
5. The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case‐control study in a Korean nationwide cohort. Cancer Medicine (2019).